Stifel Nicolaus Forecasts Strong Price Appreciation for Biogen (NASDAQ:BIIB) Stock

Posted by Defense World Staff on Feb 8th, 2026

Biogen (NASDAQ:BIIB – Get Free Report) had its price objective upped by equities research analysts at Stifel Nicolaus from $202.00 to $214.00 in a research note issued on Friday,MarketScreener reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Stifel Nicolaus’ price target points to a potential upside of 6.37% from the stock’s previous close.

BIIB has been the subject of several other research reports. The Goldman Sachs Group reissued a “buy” rating and issued a $225.00 price target on shares of Biogen in a research report on Thursday, January 8th. Morgan Stanley raised their price objective on shares of Biogen from $149.00 to $156.00 and gave the company an “equal weight” rating in a research note on Friday, December 12th. Royal Bank Of Canada reissued an “outperform” rating on shares of Biogen in a research report on Tuesday, January 13th. Wedbush upped their target price on shares of Biogen from $143.00 to $178.00 and gave the stock a “neutral” rating in a report on Friday, January 23rd. Finally, Sanford C. Bernstein set a $191.00 price target on Biogen in a research note on Tuesday. Eleven investment analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the stock. Based on data from MarketBeat, Biogen currently has a consensus rating of “Hold” and a consensus price target of $194.23.

View Our Latest Report on Biogen

Biogen Stock Performance

Shares of Biogen stock opened at $201.18 on Friday. Biogen has a one year low of $110.04 and a one year high of $202.41. The firm has a market capitalization of $29.51 billion, a price-to-earnings ratio of 22.84, a PEG ratio of 1.70 and a beta of 0.16. The business has a 50-day simple moving average of $176.94 and a 200 day simple moving average of $156.87. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.72 and a quick ratio of 2.04.

Biogen (NASDAQ:BIIB – Get Free Report) last announced its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.38. The business had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. Biogen had a return on equity of 14.13% and a net margin of 15.98%.The company’s quarterly revenue was down 7.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, research analysts anticipate that Biogen will post 15.83 earnings per share for the current fiscal year.

Insider Activity at Biogen

In other news, insider Priya Singhal sold 748 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $179.30, for a total value of $134,116.40. Following the transaction, the insider owned 6,271 shares in the company, valued at $1,124,390.30. The trade was a 10.66% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.18% of the stock is currently owned by corporate insiders.

Institutional Trading of Biogen

A number of hedge funds have recently bought and sold shares of the business. Elevation Point Wealth Partners LLC bought a new position in Biogen in the 2nd quarter valued at $25,000. WPG Advisers LLC boosted its holdings in shares of Biogen by 417.9% in the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after buying an additional 117 shares during the last quarter. Rothschild Investment LLC grew its position in Biogen by 64.7% during the second quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 88 shares during the period. Accredited Wealth Management LLC grew its position in Biogen by 1,233.3% during the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 185 shares during the period. Finally, Concord Wealth Partners increased its holdings in Biogen by 100.0% during the second quarter. Concord Wealth Partners now owns 228 shares of the biotechnology company’s stock worth $29,000 after buying an additional 114 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

Positive Sentiment: Q4 beat on both EPS ($1.99 vs. consensus ~1.72) and revenue ($2.28B vs. ~$2.21B); investors reacted favorably to the upside. BIIB Beats on Q4 Earnings & Sales, Stock Gains on Upbeat ’26 EPS View
Positive Sentiment: Biogen raised FY‑2026 adjusted EPS guidance to $15.25–$16.25, above consensus — a major driver of the rally as it signals stronger full‑year profitability expectations. Biogen forecasts annual profit above estimates as Leqembi sales pick up
Positive Sentiment: Sales of Leqembi and newer launches (Skyclarys, Zurzuvae) showed meaningful growth and helped offset MS declines, supporting upside to future revenue mix and margins. Biogen Hits 52-Week High, Alzheimer’s Drug Sales Jump
Positive Sentiment: Recent analyst support (RBC buy) and favorable coverage helped sentiment alongside the earnings/guidance beat. Biogen (BIIB) Receives a Buy from RBC Capital
Neutral Sentiment: Management released the full earnings slide deck and call transcript — useful for modeling guidance assumptions and product-level trends but not market-moving on its own. Biogen Inc. (BIIB) Q4 2025 Earnings Call Transcript
Negative Sentiment: Core MS franchise continued to decline, driving overall revenue down ~7.2% YoY; management said MS revenue pressures will persist, which limits near‑term top‑line growth. Biogen 4Q Revenue Down as Multiple Sclerosis Sales Slide
Negative Sentiment: Some outlets note Biogen “swung to a loss” on certain GAAP measures and expect continued portfolio declines, underlining execution and pricing risks in legacy products. Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles

About Biogen

(Get Free Report)

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.